Spring 2024 COVID-19 vaccination campaign: Comirnaty XBB.1.5 10 micrograms/dose vaccine for eligible children aged 5 to 11 years
Session information
- Title:
- Spring 2024 COVID-19 vaccination campaign: Comirnaty XBB.1.5 10 micrograms/dose vaccine for eligible children aged 5 to 11 years
- Description:
-
This session provides specific information about the COVID-19 vaccine for administration during the spring 2024 vaccination campaign to those aged 5 to 11 years who are eligible to receive it. The full name of the vaccine is:
Pfizer-BioNTech Comirnaty Omicron XBB.1.5 10 micrograms/dose dispersion for injection COVID-19 mRNA vaccine.
This will generally be referred to as Comirnaty XBB.1.5 10 micrograms/dose throughout this session. It is only suitable for administration to eligible children aged 5 to 11 years.
This session is designed to provide healthcare workers with the knowledge they need to administer these vaccines safely and effectively to eligible children.
It will cover key information including how the vaccine works, how the vaccine should be stored, prepared and administered and any contraindications, precautions and potential vaccine reactions.
The Core Knowledge session covers key areas including legal aspects of vaccination. The Core Knowledge session must therefore be completed in addition to this vaccine-specific session by any staff member new to COVID-19 vaccination. It may also be freely consulted by experienced COVID-19 vaccinators wishing to revise any aspect of their knowledge.
After completing this session about the 2024 spring vaccination campaign for children aged 5 to 11 years, you should complete the accompanying knowledge assessment.
It is important to note that the different types of COVID-19 vaccine have different storage, preparation and administration requirements. Vaccines produced by the same manufacturer, including those with similar brand names, may, too, have different requirements. You must be familiar with the specific recommendations for the COVID-19 vaccine(s) you are delivering. Separate vaccine-specific e-learning sessions for children aged 6 months to 4 years and for adults and young people aged 12 years and above are available. - Hierarchy:
- Coronavirus (COVID-19) > COVID-19 Vaccination > Spring 2024 COVID-19 vaccination campaign: Comirnaty XBB.1.5 10 micrograms/dose vaccine for eligible children aged 5 to 11 years > Spring 2024 COVID-19 vaccination campaign: Comirnaty XBB.1.5 10 micrograms/dose vaccine for eligible children aged 5 to 11 years
- Author(s):
-
Lesley McFarlane
Laura Craig
- Created:
- 17 Jan 2022
- Last Major Update:
- 9 Apr 2024
- Keywords:
- 099-0009, COVID, 19, coronavirus, vaccine, vaccination, immuniser, immunisation, Pfizer, children, five to eleven year olds, vaccinating children, Comirnaty 10 micrograms/dose
- Quicklink:
- 099-0009
Share this item
- Copy URL
Overall rating
4.6/5
4.6/5
Content
4.7/5
4.7/5
Presentation
4.6/5
4.6/5
Interactivity
4.6/5
4.6/5
Self assessments
4.5/5
4.5/5
Overall rating
4.6/5
4.6/5
Content
4.7/5
4.7/5
Presentation
4.6/5
4.6/5
Interactivity
4.6/5
4.6/5
Self assessments
4.5/5
4.5/5
- Title:
- Spring 2024 COVID-19 vaccination campaign: Comirnaty XBB.1.5 10 micrograms/dose vaccine for eligible children aged 5 to 11 years
- Description:
-
This session provides specific information about the COVID-19 vaccine for administration during the spring 2024 vaccination campaign to those aged 5 to 11 years who are eligible to receive it. The full name of the vaccine is:
Pfizer-BioNTech Comirnaty Omicron XBB.1.5 10 micrograms/dose dispersion for injection COVID-19 mRNA vaccine.
This will generally be referred to as Comirnaty XBB.1.5 10 micrograms/dose throughout this session. It is only suitable for administration to eligible children aged 5 to 11 years.
This session is designed to provide healthcare workers with the knowledge they need to administer these vaccines safely and effectively to eligible children.
It will cover key information including how the vaccine works, how the vaccine should be stored, prepared and administered and any contraindications, precautions and potential vaccine reactions.
The Core Knowledge session covers key areas including legal aspects of vaccination. The Core Knowledge session must therefore be completed in addition to this vaccine-specific session by any staff member new to COVID-19 vaccination. It may also be freely consulted by experienced COVID-19 vaccinators wishing to revise any aspect of their knowledge.
After completing this session about the 2024 spring vaccination campaign for children aged 5 to 11 years, you should complete the accompanying knowledge assessment.
It is important to note that the different types of COVID-19 vaccine have different storage, preparation and administration requirements. Vaccines produced by the same manufacturer, including those with similar brand names, may, too, have different requirements. You must be familiar with the specific recommendations for the COVID-19 vaccine(s) you are delivering. Separate vaccine-specific e-learning sessions for children aged 6 months to 4 years and for adults and young people aged 12 years and above are available. - Hierarchy:
- Coronavirus (COVID-19) > COVID-19 Vaccination > Spring 2024 COVID-19 vaccination campaign: Comirnaty XBB.1.5 10 micrograms/dose vaccine for eligible children aged 5 to 11 years > Spring 2024 COVID-19 vaccination campaign: Comirnaty XBB.1.5 10 micrograms/dose vaccine for eligible children aged 5 to 11 years
- Author(s):
-
Lesley McFarlane
Laura Craig
- Created:
- 17 Jan 2022
- Last Major Update:
- 9 Apr 2024
- Keywords:
- 099-0009, COVID, 19, coronavirus, vaccine, vaccination, immuniser, immunisation, Pfizer, children, five to eleven year olds, vaccinating children, Comirnaty 10 micrograms/dose
- Quicklink:
- 099-0009